-
Mashup Score: 2HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients - 23 hour(s) ago
May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the first time that coronary CTA (CCTA) with fractional flow reserve (FFRCT) care significantly reduces mortality by over 60 percent at five years in patients with PAD undergoing major vascular surgery, far surpassing the current standard of care.1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years.2-4 HeartFlow’s non-invasive FFRCT technology has emerged as a leading frontline strategy for accurately diagnosing hemodynamically significant coronary lesions in patients suspected of having CAD.5 Revascularization to improve blood flow to the heart has been shown to reduce mortality in stable chest pain patients.6 This novel study marks a significant mile
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 14C Medical's AltaValve System Secures Dual FDA Breakthrough Device Designations, Expediting Patient Access to Advanced Mitral Valve Therapies - 23 hour(s) ago
May 8, 2024 — 4C Medical Technologies, Inc. (“4C Medical”), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for the AltaValve System, a transcatheter mitral valve replacement (TMVR) device. Among other benefits, Breakthrough Device designation expedites the review process, shortening the time until technology reaches patients if approved by the FDA. Specifically, the FDA granted the AltaValve System Breakthrough Device designations for two therapeutic indications: Treatment of moderate-to-severe or severe mitral regurgitation (MR), and Treatment of moderate-to-severe or severe MR with moderate/severe mitral annular calcification (MAC). MR occurs when blood flows backward through the mitral valve and into the atrium each time the left ventricle contracts. If left untreated, MR can lead to heart failure or death. Due to the complexity
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research - 23 hour(s) ago
May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH). This was done in preclinical models, but could apply to humans for whom PAH is rare but fatal and affects predominantly younger women. The study was published today in Circulation Research, an American Heart Association journal, with Stefanos Zafeiropoulos, MD PhD, as the lead author and Stavros Zanos, MD PhD, as the senior author. The research adds to the growing scientific evidence of bioelectronic medicine and neuromodulation as an effective therapy to treat diseases with an inflammatory component. The study, titled “Ultrasound neuromodulation of an anti-inflammatory pathway at the spleen produces sustained improvement of experimental pulmonary hype
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
May 7, 2024 — RapidAI, the global leader in developing clinically deep Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration (FDA) has granted 510(k) clearance for its AngioFlow by RapidAI solution. The module delivers perfusion imaging analysis directly within the interventional suite to promote greater clinical confidence, workflow efficiency, and potentially improve patient outcomes. “We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite,” said Karim Karti, CEO of RapidAI. “Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of U.S. stroke pati
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4Documentary Led by HonorHealth Research Institute Focuses on Injuries to Doctors and Nurses Working in Cardiology - 2 day(s) ago
May 7, 2024 — HonorHealth Research Institute’s David G. Rizik, M.D., narrates and is a co-producer of a documentary focused on radiation and orthopedic injuries suffered by doctors and nurses who work in cardiac catheterization laboratories where they apply the very latest non-surgical technologies to treat the world’s leading cause of death, heart disease. The premier of a two-hour, six-part version of Scattered Denial: The Occupational Dangers of Radiation will stream beginning Sunday, April 28, on www.ScatteredDenial.org, preceding a one-hour version that will air nationally in July on PBS. “The ‘scatter’ is radiation scatter, and ‘denial’ is how we’ve denied that this was happening until it was too late,” said Dr. Rizik, research director of the Cardiovascular Research Division at HonorHealth Research Institute, the world’s leader in studies tracing the dangers of occupational radiation exposure among medical professionals, and how they can be protected by a new class of radiation
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Medtronic TAVR Outcomes from SMART Trial and Optimize PRO Addendum on Evolut TAVR Presented at SCAI 2024 Scientific Sessions - 2 day(s) ago
May 7, 2024 — Medtronic announced the release of important clinical outcomes in two leading transcatheter valve therapies from studies presented at the recent Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions, SCAI 2024, held May 2-4 in Long Beach, CA. Medtronic transcatheter therapies showed excellent outcomes in the treatment of congenital heart disease and severe aortic stenosis, as reported in a written statement released by the company and summarized below. “The data presented at SCAI 2024 reinforces our commitment to providing solutions for structural heart patients with varying and complex anatomies,” said Nina Goodheart, senior vice president and president, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. Goodheart added, “We are seeing positive outcomes for patient groups in need of minimally invasive solutions – including meaningful insights into the benefits of the Harmony TPV system and additional evidence
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 1
May 7, 2024 — A new study by a global team of researchers, led by Sook-Lei Liew, PhD, of USC’s Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), has revealed that areas of age-related damage in the brain relate to motor outcomes after a stroke—a phenomenon that may be under-recognized in stroke research. The study was published online on May 3, 2024, in Neurology, the medical journal of the American Academy of Neurology. A stroke often leads to motor impairment, which is traditionally linked to the extent of damage to the corticospinal tract (CST), a crucial brain pathway for motor control. Signaling along the CST is involved in a variety of movements, including walking, reaching, and fine finger movements like writing and typing. However, stroke recovery outcomes aren’t fully predicted by damage to the CST, suggesting other factors are at play. The new observational study from the Enhancing Neuroimaging Genetics through Meta-Analysis (ENIGMA) Stroke Recovery
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
May 7, 2024 — Women and black patients were less frequently treated with minimally invasive therapy compared to men or non-Black patients, according to new data from the REAL-PE analysis which investigated catheter-based pulmonary embolism (PE) treatment. The late-breaking results were presented in a session, “Disparities in Pulmonary Embolism Care: Insights from Big Data Analytics” during the recently-held Society for Cardiovascular Angiography & Interventions SCAI 2024 Scientific Sessions. A snapshot summary of the outcomes, as presented in a written statement issued by SCAI, follows. Study Summary REAL-PE analyzed data from patients within the Truveta database diagnosed with PE and treated with USCDT or MT for PE. Patient characteristics including race, ethnicity, age, sex, comorbidities, and prior diagnoses were assessed to investigate their association with the type of treatment used. Of the more than 430,000 patients diagnosed with PE, about 2,000 patients analyzed were treated w
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative patient care in the cardiovascular segment has announced a strategic partnership with HeartX, a pioneering MedTech company focused on research and development. Through this collaboration, SMT gains an innovative product line in the Congenital Heart Defect space. This collaboration not only broadens SMT’s advanced product offerings within the Congenital Heart Defect space but also marks a significant stride toward revolutionizing healthcare on a global scale. HeartX’s portfolio includes advanced products like the JOVE VB Stent for Sinus Venous ASD, JOVE Versatile ASD (VASO), Fenestrated VASO and JOVE PFO, with ongoing developments in PDA and VSD closures as well as advanced visualization systems for structural interventions. The collaboration between SMT and HeartX aims to address gaps in current medical procedures by prioritizing simplicity, efficiency, and cost reductio
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0Teleflex Announces the Limited Market Release of the Wattson Temporary Pacing Guidewire - 3 day(s) ago
May 6, 2024 — Teleflex Incorporate, a leading global provider of medical technologies, today announced that the Wattson Temporary Pacing Guidewire limited market release has commenced at Columbia University Irving Medical Center. The first cases were performed by Dr. Tamim Nazif, Director of Clinical Research, Dr. Susheel Kodali, Professor of Medicine and Director of the Structural Heart and Valve Center, and Dr. Isaac George, Surgical Director of the Heart Valve Center. Featuring a simple design to create procedural efficiencies, the Wattson Temporary Pacing Guidewire offers dual functionality, supporting both valve delivery and ventricular bipolar pacing during structural heart procedures, including transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV). The device offers a procedural alternative designed to avoid potential complications1, steps1, and costs2 associated with traditional right ventricular pacing. From its flexible distal pigtail shape to i
Source: www.dicardiology.comCategories: General Medicine News, CardiologistsTweet
@DAICeditor @HeartFlow HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent #Mortality Reduction with #FFRCT-Guided Care in #PAD Patients: https://t.co/RC2nTEaiI2